133 results about "Microbial biomarkers" patented technology

The invention relates to the field of forensic medicine, and discloses a method and system for identifying smoking behaviors and application of the method and system. The construction method comprises the following steps: respectively obtaining saliva and excrement of a smoking object and a non-smoking object; performing metagenome sequencing to obtain original microbiome data; after processing the original microbiome data, extracting multi-omics feature information, including species information and gene function annotation information; based on a statistical analysis method, carrying out diversity analysis and screening microbial markers and functional genes significantly related to smoking behaviors; constructing a training set and a test set, and training a machine learning model and model evaluation by taking the microbial markers and / or the functional genes as input features; and performing smoking behavior identification on a target sample by using the model, and outputting a prediction result. The accuracy rate of model identification reaches 0.7966, the sensitivity is 0.8750, the specificity is 0.7037, and the method can be applied to health assessment and judicial expertise.

The invention discloses a microbial marker related to refractory diarrhea, a product and application of the microbial marker, and relates to the technical field of biomedicine. According to the present invention, the microbial marker comprises any one or more of Ruminococcus sp, Bifidobacterium longum, Lachnospiraceae bacterium, Klebsiella pneumoniae, Rosa mucilaginosa, and Coprococcus catenus, and the microbial marker comprises any one or more of the following components: the Ruminococcus sp, the Bifidobacterium longum, the Lachnospiraceae bacterium, the Klebsiella pneumoniae, the Rosa mucilaginosa, and the Coprococcus catenus. The microbial marker can serve as a detection marker to be applied to diagnosis of refractory diarrhea patients, and when the refractory diarrhea patients are diagnosed, the microbial marker is completely noninvasive and high in accuracy.

The invention discloses a meningioma saliva microbial marker, a product and application of the meningioma saliva microbial marker, and belongs to the field of biological medicine. The saliva microbial marker is prepared from one or more of fusobacterium periodontium, neisseria microflavus, and Streptococcus cristatum, and the saliva microbial marker is prepared from one or more of the following components: the fusobacterium periodontium, the neisseria microflavus, and the Streptococcus cristatum, and the saliva microbial marker is prepared from one or more of the following components: the Saccharomyces cerevisiae, the Saccharomyces cerevisiae, the Saccharomyces cerevisiae and the Saccharomyces cristatum. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the saliva microbial marker. The invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of meningioma, and provides a new tool for clinical diagnosis.

The invention discloses a brain glioma intestinal microbial marker, a product and application of the brain glioma intestinal microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized by being prepared from one or more of Eubacter algenti, Prevotella copri, Alistipes finegili, Bifidobacterium adolescentis and Citrobacter sp., and the enteric microbial marker is prepared from one or more of Eubacter algenti, Prevotella copri, Alistipes finegili, Bifidobacterium adolescentis and Citrobacter sp., and the enteric microbial marker is prepared from one or more of Eubacter algenti, Prevotella copri, Alistipes finegili, Bifidobacterium adolescentis and Citrobacter sp. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing brain glioma and a computer program product related to the brain glioma. The product provided by the invention has good feasibility and accuracy, and provides a new tool for clinical diagnosis.

The invention discloses an esophageal adenocarcinoma plasma circulation microbial marker combination, a reagent, a kit, a risk prediction model and application thereof, and belongs to the cross technical field of liquid biopsy and microbiomics. The esophageal adenocarcinoma plasma circulating microbial marker combination disclosed by the invention comprises enterobacteriaceae, cilia, prevotella, ackermania, lactobacillus fermentum and streptococcus. When the esophageal adenocarcinoma plasma circulating microbial marker combination is used for verifying esophageal adenocarcinoma patients and healthy controls, the AUC is 0.952, the sensitivity is 100%, the specificity is 80.00%, the accuracy is 91.43%, the positive predictive value is 86.96%, and the negative predictive value is 100%; the esophageal adenocarcinoma plasma circulating microbial marker combination can effectively distinguish esophageal adenocarcinoma patients from healthy people, is suitable for early screening of esophageal adenocarcinoma, and has remarkable clinical screening application value.

The invention discloses an intestinal microbial marker related to non-alcoholic fatty liver, a product and application of the intestinal microbial marker, and belongs to the field of biological medicine. The microbial marker is prepared from one or more of streptococcus anginiae, bacteroides faecalis, bifidobacterium adolescentis and hispidaceae bacteria. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the microbial marker. The invention further provides a product for diagnosing the non-alcoholic fatty liver disease, a prediction system for evaluating the risk that a to-be-detected object is a patient with the non-alcoholic fatty liver disease, and a computer program product related to the non-alcoholic fatty liver disease. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of the non-alcoholic fatty liver disease, and provides a new tool for clinical diagnosis.

The invention discloses a meningioma enteric microbial marker, a product and application of the meningioma enteric microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized by being prepared from one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and is characterized in that the enteric microbial marker comprises one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and the enteric microbial marker comprises one or more of parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of meningioma, and provides a new tool for clinical diagnosis.

The invention provides a plurality of microbial markers for cervical cancer and an application of the microbial markers. The microbial markers comprise 11 bacteria, namely, Porphyromonas aeruginosa, Lactobacillus crispatus, Klebsiella pneumoniae, Gemerella haemolysms and the like, and the microbial markers comprise 11 bacteria, namely, the Porphyromonas aeruginosa, the Lactobacillus crispatus, the Klebsiella pneumoniae, the Gemerella haemolysms and the like. According to the method, the threshold value of the output risk value is obtained according to the trained random forest model, and then the probability value that the cervical lesion sample is the high-risk lesion can be obtained only by obtaining the relative abundance of the screened 11 genital tract microbial markers and inputting the relative abundance into the established random forest model. The machine learning model is constructed based on 16S sequencing, the high risk of cervical cancer can be recognized in time, the method is used for auxiliary diagnosis of cervical cancer patients, early discovery, early prevention and early treatment of cervical cancer are facilitated, and the accessibility of cervical cancer screening is improved.

The invention discloses a methane leakage microbial marker mining method based on multi-source data fusion and related equipment, according to the embodiment of the invention, a multi-dimensional feature space is constructed by fusing microbial gene data, spatial information and environmental geochemical data, and the data dimension and reliability of marker mining are improved; moreover, according to the embodiment of the invention, a mode of combining random forest and regression modeling is adopted, so that quantitative screening of the markers is realized, and manual intervention and subjective deviation are reduced; specifically, according to the embodiment of the invention, the markers are graded on the basis of comprehensive scores of three dimensions of importance, stability and universality, so that priority selection in subsequent practical application is facilitated; the embodiment of the invention is suitable for methane leakage identification of different sea areas and different geological backgrounds, has good generalizability and practicability, and can be widely applied to the technical field of marker analysis.

The invention relates to the technical field of biological detection, and particularly discloses a microbial marker combination for predicting neoadjuvant chemotherapy sensitivity of colorectal cancer and application of the microbial marker combination, and the microbial marker combination comprises treponema, staphylococcus, streptococcus, facultative diplococcus and fusobacterium. The invention further discloses a method for predicting the neoadjuvant chemotherapy sensitivity of colorectal cancer and application of the microbial marker combination for predicting the neoadjuvant chemotherapy sensitivity of colorectal cancer and application of the microbial marker combination for predicting the neoadjuvant chemotherapy sensitivity of colorectal cancer, and the microbial marker combination comprises treponema, staphylococcus, streptococcus, facultative diplococcus and fusobacterium. According to the application, by analyzing the microbial community composition in the tumor microenvironment of the colorectal cancer patient, the microbial marker related to the neoadjuvant chemotherapy sensitivity is identified, the patient insensitive to neoadjuvant chemotherapy can be accurately predicted based on the microbial marker combination disclosed in the application, the treatment risk is reduced, the invalid treatment is reduced, and the treatment effect is improved. And a reliable basis is provided for formulating precise personalized treatment.

The invention provides a microbial marker and a prediction model for schizophrenia with social anxiety disorder. The microbial marker is a Bacteroides microorganism in saliva. The relevance between the relative abundance of Bacteroides microorganisms in saliva and social anxiety disorder is found for the first time. A Nomogram clinical prediction mode is formed by taking the specific microbial marker as a microbial marker in combination with a children bad experience scale and 6-hydroxymelatonin and 5-hydroxyindoleacetic acid in serum, so that objective biological indexes can be provided for early diagnosis and monitoring of whether schizophrenia is accompanied by social anxiety disorder or not; errors of subjective evaluation are reduced; moreover, the oral saliva sample has the obvious advantage of being easy to collect for psychiatric patients, the working difficulty of medical staff can be greatly reduced, and revolutionary changes of prediction, diagnosis and treatment of schizophrenia accompanied with social anxiety disorder are expected to be brought.

The invention relates to the field of oral cavities, in particular to a biomarker for drug-related jawbone necrosis and application of the biomarker. The invention provides application of a biomarker to preparation of a drug-related jawbone necrosis detection product. The biomarker comprises an oral metabolite and an oral flora, the oral metabolite comprises one or a combination of more of spermine, 7-methylguanine, hypoxanthine, quinoline and taurine. And the oral flora comprises bacteria of bacteroides, peptostreptococcaceae, porphyrinomonas, butyric acid vibrio, micromonas and moniliaceae, and the oral flora comprises bacteria of bacteroides, peptostreptococcaceae, porphyrinomonas, butyric acid vibrio. According to the application, metabolite and microorganisms which are characteristic-changed in an MRONJ microenvironment are discovered, the pathogenesis that the metabolite and the microorganisms possibly participate in the MRONJ is predicted, the risk that an individual suffers from the MRONJ is expected to be judged in an early stage through oral metabolite and microorganism marker screening, occurrence of the MRONJ is prevented by adjusting a medication strategy or modifying oral flora in time, and the MRONJ is prevented from being damaged by the oral metabolite and the microorganism. Therefore, the method is of great significance to formulating a new osteoporosis clinical prevention and treatment strategy.

The invention discloses a liver cirrhosis microbial marker as well as a screening method and application thereof, and solves the technical problems of few markers, small clinical queue scale and unknown effectiveness in predicting the future liver cirrhosis risk in the existing intestinal flora biomarker research. The method comprises the following steps: by integrating whole genome association research data (GWAS) and 16S rRNA gene sequencing data, screening out candidate microbial differential bacteria related to liver cirrhosis by adopting difference analysis; in combination with LDSC analysis and a double-sample Mendel randomization method, MR related bacteria and LDSC genetic related bacteria are screened from the aspects of causal correlation and genetic correlation; taking an intersection of the differential bacteria, the MR related bacteria and the LDSC genetic related bacteria as a marker; finally, model training is conducted through a machine learning algorithm by means of a data set with sample labels, individual liver cirrhosis risk prediction labels are output, early screening of liver cirrhosis is achieved, and the method can be widely applied to the technical field of intestinal microorganism and data mining.

The invention relates to the field of molecular diagnosis and tumor risk assessment, in particular to a marker combination and a kit for assessing the lymphatic metastasis risk of cervical cancer and application of the marker combination and the kit. The marker comprises a group of gene markers and a group of microbial markers, the gene markers comprise CARD9, MNX1AS2, MRAS, OLFML2A and RPS28, preferably, the gene markers further comprise at least one of CFL1P1 and GRASLND, and the microbial markers comprise microorganisms of the genus Dialister, the genus Catonella and the genus Campylobacter. The marker provided by the invention can be used for constructing an accurate risk assessment model, and can be used for developing a corresponding PCR (Polymerase Chain Reaction) kit, a mass spectrum or a chromatographic analysis system to realize metastasis risk prediction, curative effect assessment and new drug screening of cervical cancer patients.

The invention discloses a multi-omics-based coronary heart disease hierarchical diagnosis system and application thereof, and relates to application of personal information in a system for diagnosing whether a subject has no coronary heart disease (NCA) or suffers from the coronary heart disease, and the coronary heart disease comprises stable coronary heart disease (sCAD) and acute coronary syndrome (ACS). The multi-dimensional feature set is constructed by integrating clinical, microbial and metabolic features, potential information provided by data of different dimensions is fully utilized, and the diagnostic performance of the model is remarkably improved; through a Boruta algorithm and an SHAP framework, a series of new metabolite and microbial biomarker information is found, and the method can be used for accurately distinguishing the coronary heart disease and the stable coronary heart disease acute coronary syndrome.

The application relates to the field of biotechnology and health informatics, and particularly discloses a microorganism marker combination for detecting obstructive sleep apnea of children and application thereof. The microorganism marker combination comprises the following nine microorganism genera: g__Streptococcus, g__Solobacterium, g__Schaalia, g__Capnocytophaga, g__Stomatobaculum, g__Mogibacterium, g__Clostridia_UCG-014, g__Selenomonas and g__Pseudoleptotrichia. By detecting the relative abundance of the above microorganism genera in a saliva sample of a child, a classification model is constructed by using a random forest algorithm, non-invasive and objective screening of OSA of the child is realized, and the application has high accuracy and clinical application value.

The invention relates to the technical field of biological detection, in particular to a microbial marker for evaluating visceral obesity, application of the microbial marker, a kit, an evaluation model and a system. The microbial marker is prepared from Faecalibacteria, and the microbial marker is prepared from Faecalibacteria. According to the microbial marker for evaluating visceral obesity, and the detection reagent, the kit, the evaluation model and the system based on the marker, rapid, safe and accurate evaluation of visceral obesity can be realized.

The invention relates to the field of medical detection, in particular to a microbial marker composition for predicting prognosis of hepatocellular carcinoma and application of the microbial marker composition. Advanced bioinformatics analysis, including linear discriminant analysis effect size and Cox proportional risk regression, is utilized to determine the correlation between specific microorganisms and clinical results of HCC patients, and further explore the relationship between the spectrum of microorganisms in tumor tissues and gene expression so as to clarify the potential approach that the microorganisms may affect HCC progress; the microbe prognosis characteristic model is developed by utilizing the analysis so as to improve the prediction on the survival of the patient, the influence of the related microbiota in the HCC tumor on the immune condition is also explored, and information can be provided for formulating an immunotherapy strategy. According to the invention, by comprehensively analyzing the attributes and prognosis of the microorganisms in the HCC, the understanding of the tumor microenvironment of the HCC is enhanced, so that the formulation of a more accurate and personalized cancer management strategy is promoted.

The present invention belongs to the field of biomedicine and discloses a group of microbial markers for diagnosing idiopathic membranous nephropathy and their applications, and specifically relates to the application of intestinal microbial markers in the diagnosis of idiopathic membranous nephropathy. The present invention, by performing 16S rRNA sequencing on fecal samples of subjects with idiopathic membranous nephropathy, discovered for the first time that 19 types of microbial assemblies are associated with idiopathic membranous nephropathy, suggesting that early diagnosis of idiopathic membranous nephropathy can be achieved by detecting the abundance of 19 types of microorganisms.

The invention discloses a vagina microbial marker combination, which is characterized in that the vagina microbial marker combination is composed of Lactobacillus indices and Bifidobacterium dentium, and the vagina microbial marker combination is used for assisting in evaluating the premature delivery risk of a pregnant woman suffering from cervical insufficiency and subjected to transvaginal cervical cerclage. Therefore, the premature delivery can be predicted based on the vagina microbial marker combination, so that decisions and help are provided for clinicians to judge whether the pregnant woman is premature delivery or not.

The application discloses a kind of adolescent autism intestinal microorganism marker and application thereof, belong to the field of biological medicine.The microorganism marker includes one or more of Ruminococcus gnavus, Streptococcus thermophilus, Streptococcus salivarius, Butte's intestinal bacillus, pet big anaerobic clavulanic acid bacteria and Prevotella pittmanniae.The application provides a kind of product (such as kit), including detection reagent for detecting the relative abundance of the microorganism marker.The product provided by the application has good feasibility and accuracy, and can effectively evaluate whether adolescent has the risk of autism, provides a new tool for clinical diagnosis.

The invention discloses a method and a system for tracing a grain production place based on microbial fingerprints. The method comprises the following steps: collecting a grain sample and acquiring microbial fingerprint information of the grain sample; constructing a training set and a test set based on the microbial fingerprint information; inputting the training set into a random forest learning framework, performing training by taking the grain producing area as a prediction target and the microbial fingerprint data as an input variable, generating a random forest prediction model, and verifying the performance of the random forest prediction model by using the test set; based on the trained random forest prediction model, calculating the importance score of each microorganism characteristic, and screening out the microorganism characteristic with high importance as the key microorganism marker of the grain production area; using the screened key microbial marker features to train a grain origin traceability model, and verifying the performance of the model on the independent test set again; and acquiring microbial fingerprint information of to-be-detected grains, and inputting the microbial fingerprint information into the grain origin traceability model to obtain a traceability result of the grain origin of the to-be-detected grains.

The invention relates to an internal reference sequence, a primer probe composition, a kit, a method and application for quantitatively detecting a caries microbial marker of an underage child, and belongs to the fields of oral prophylactic medicine and oral public health. The method solves at least one of the problems of low sensitivity, poor specificity, poor repeatability, poor anti-interference capability, low detection speed, high cost and the like in the existing low-age child caries microbial marker detection. The invention relates to a 16S internal reference sequence for quantitatively detecting a caries microbial marker of young children. The internal reference sequence comprises an upstream primer sequence, a downstream primer sequence and a probe sequence. According to the invention, the sensitivity, the specificity, the repeatability, the anti-interference capability and the detection speed of caries microorganism detection are improved, and the cost is reduced.

The invention discloses a microbial marker for treating recurrent clostridium difficile infection based on coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker comprises the following components: Dorea longigena, Alistipes putredinis, Citrobacter farmeri, Coprococcos, Eubacter coprostanoliganes, Agatrobacter rectas, Dorea foetida, Blauria obbe, Klebsiella foetida, Blauria foetida, Blauria ovaticus and Gemmigerformation. The microbial marker comprises the following components: Dorea longigena, Alistipes putredinis, Citrobacter farmeri, Citrobacter coprostanoliganes, Citrobacter rectas, according to the invention, through metagenome sequencing and a machine learning algorithm, key microbial markers significantly related to recurrent clostridium difficile symptom improvement in the coprophilous fungus transplantation treatment process are screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of recurrent clostridium difficile infection.

The invention provides application of helispirillum as a target spot in detection and promotion of hot habit. Through systematic metagenomics analysis on excrement samples of people in a hot area and control people in a warm area, and through difference comparison and verification research, a characteristic microbial marker, namely, helispirillum, which is remarkably related to a hot habit state is identified for the first time. The method can accurately reflect the adaptive state of an individual to the thermal environment, and can be used for non-invasive evaluation or auxiliary detection of the thermal habit degree. Based on the marker, the probability that an individual is in a hot habit state or a non-habit state can be quantitatively evaluated, and a new biomarker detection method is provided for objective diagnosis of hot habit.

The application discloses a microorganism marker combination for identifying nest susceptibility of chickens and application thereof, and belongs to the technical field of poultry breeding and microbiomics. The microorganism marker combination comprises relative abundance information of at least two bacterial phyla in Bacteroidetes, Firmicutes and Verrucomicrobia in cecal contents. When at least two of the following conditions are met: the abundance of Bacteroidetes is higher than 35%, the abundance of Firmicutes is lower than 35%, and the abundance of Verrucomicrobia is lower than 2%, it is determined that the chicken has nest susceptibility or is in a nest period. Based on the marker combination, the application provides a corresponding identification method, a regulation method and a regulation agent screening strategy.

The invention provides a microbial marker for schizophrenia with social anxiety disorder and application of the microbial marker. The microbial marker is a deinococcus microorganism in saliva. The relevance between the content of the deinococcus microorganisms in saliva and social anxiety disorder is found for the first time. Moreover, by taking deinococcus microorganisms in saliva as potential microbial markers, objective biological indexes can be provided for early diagnosis and monitoring of the schizophrenia accompanied with social anxiety disorder, and errors of subjective evaluation are reduced; moreover, compared with the intestinal specific biomarker, the oral saliva sample has the obvious advantages of easiness in collection and the like for psychotic patients, and the working difficulty of medical personnel can be greatly reduced; besides, the specific microbial marker can be combined with a traditional psychological scale and other biomarkers to form a more comprehensive diagnosis mode, and revolutionary changes of prediction, diagnosis and treatment of schizophrenia with social anxiety disorder are expected to be brought.

The present invention discloses the application of microbial markers in the diagnosis of hyperglycemia-related diseases. The microbial markers include Prevotella_stercorea, Eubacterium_rectale_CAG.36, Dorea_longicatena, Butyrivibrio_crossotus, Klebsiella_pneumoniae, Bacteroides_caccae, and Roseburia_intestinalis. By detecting the content, abundance, or genomic base mutation frequency of the microbial markers in a subject's sample, it is possible to predict or diagnose whether the subject has a hyperglycemia-related disease or the risk of developing a hyperglycemia-related disease. The present invention has good application prospects in the diagnosis of hyperglycemia-related diseases.

The present application relates to the technical field of microorganism and the technical field of medicine, and particularly relates to an oral microorganism marker and application thereof in diagnosis of prognosis of gastric cancer. The oral microorganism marker comprises at least one of Aggregatibacter, Filifactor, Moryella and Leptotrichia. The present application firstly discovers that the level of human oral flora changes in different prognosis outcomes of gastric cancer, and by detecting the change of the flora, the prognosis survival period of the patient with gastric cancer can be predicted. The oral microorganism marker has the advantages of high specificity and strong sensitivity in diagnosis. The present application proves the clinical correlation of the oral microorganism flora in the prognosis of gastric cancer, and provides a non-invasive and highly sensitive tool for identifying the patient at risk of poor outcome before treatment.

This application discloses a combination of gut microbial biomarkers, a system, and its application for detecting liver injury in fish, belonging to the field of molecular detection technology for fish liver injury. The gut microbial biomarker combination includes *Cetobacter* spp. (…). Cetobacterium ), Pseudomonas spp. Pseudomonas ) and Escherichia coli-Shigella spp. Escherichia‑Shigella Using the intestinal microbial biomarker combination described in this application, non-invasive diagnosis of liver damage can be achieved without touching the fish body, with high accuracy and no missed detections, especially avoiding misdiagnosis as liver damage that could lead to overtreatment. This provides a basis for judgment in aquaculture environment control and precise disease prevention and control, and is beneficial for improving the survival rate and profitability of yellow catfish farming.